We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > PIXUVRI

News List

Servier terminates CTI cancer pact following clinical failure fiercebiotech
February 28, 2019
Servier has terminated its Pixuvri collaboration agreement with CTI BioPharma. The action comes seven months after the B-cell non-Hodgkin lymphoma drug failed a key clinical trial....
CTI BioPharma Corp. Restructures contractpharma
December 17, 2018
CTI BioPharma Corp. is restructuring in an effort to improve efficiencies and reduce costs. As part of the plan, workforce reductions have been implemented that impact approximately 50 percent
CTI, Servier’s Pixuvri fails in post-marketing trial pharmatimes
July 16, 2018
A late-stage trial of Servier and CTI BioPharma’s Pixuvri in combination with Roche's MabThera has failed to hit targets in B-cell non-Hodgkin lymphoma, putting its conditional approval in Europe in jeopardy.
Servier and CTI BioPharma Expand Pixuvri Agreement americanpharmaceuticalreview
April 27, 2017
Servier and CTI BioPharma announced that they agreed to expand their existing license and development collaboration agreement for Pixuvri.